Effects of Indian Mitotane in the treatment of cortical cancer

In the global anti-tumor drug system, Mitotane has long been regarded as a rare but critical drug in the treatment of adrenocortical cancer (ACC; adrenal cancer). However, when many patients are looking for "Indian mitotane", they will find a special phenomenon: there is no generic version of mitotane in the Indian market. This is not an accident of the supply chain, but is related to drug research and development monopoly, global production capacity constraints and regulatory system. The international drug database shows that mitotane is currently mainly produced by original research companies and is a highly specific drug. Its manufacturing process is complex and requires extremely high purity and impurity control, so the global supply is limited. For this reason, it is often listed as one of the “scarce anti-tumor drugs” on international medical forums and professional pharmacy websites, and many countries rely on imported supplies.

Although "Indian mitotane" does not exist, but what patients are really concerned about is its ability to treat cortical cancer. Judging from the long-term summary of overseas professional oncology websites, mitotane’s status is almost irreplaceable. It is a drug that has a targeted destructive effect on adrenocortical cells. It can intervene in the corticosteroid synthesis chain, help inhibit tumor growth, reduce cortisol levels in the body, and improve a series of symptoms caused by hormone overdose. In patients with inoperable locally advanced or metastatic ACC, mitotane is often regarded as the mainstay of systemic treatment, and its mechanism of action has been demonstrated many times in international medical data.

In addition, the therapeutic effect of mitotane is closely related to its cumulative exposure and sustained and stable plasma concentration. Many institutions provide"drug concentration monitoring" as a necessary part of treatment, which is also a reflection of the complexity of this drug. It is difficult for generic drugs that lack this monitoring system to meet treatment requirements, which may be one of the reasons why they are not produced in India. For patients who really need mitotane, formal original research supply channels are still the most reliable choice.

Reference materials:https://go.drugbank.com/drugs/DB00648